top of page

SR-aGvHD

Steroid-Refractory acute Graft Versus Host Disease

2.png

  • Allogeneic hematopoietic stem cell transplantation (HSCT) is a potential therapy for intractable hematological diseases in which donor HSCs are intravenously administered to recipients.

​

  • Transplanted HSCs migrate to the recipient's bone marrow where they differentiate into platelets, red blood cells, and white blood cells.

​

  • GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host cells as foreign and attack them. aGvHD occurs in approximately 50% of allogeneic HSCT recipients.

​

  • Although 50% of patients with aGvHD can be treated with steroids, the remaining patients who do not respond to immunosuppressants, including steroids, may eventually succumb to this disease.

그림6.png

  • In a non-clinical study, compared with naïve mesenchymal stem cell (MSC) treatment, IntenCell® treatment significantly increased the survival rate of aGvHD mice and increased the survival rate more than two-fold.

​

  • Currently, SR-aGvHD treatment using IntenCell® is undergoing a phase 1 clinical trial and will soon be commercialized.

bottom of page